CN115501328A - Sodium azulene sulfonate chitosan gel and preparation process thereof - Google Patents

Sodium azulene sulfonate chitosan gel and preparation process thereof Download PDF

Info

Publication number
CN115501328A
CN115501328A CN202211058532.1A CN202211058532A CN115501328A CN 115501328 A CN115501328 A CN 115501328A CN 202211058532 A CN202211058532 A CN 202211058532A CN 115501328 A CN115501328 A CN 115501328A
Authority
CN
China
Prior art keywords
parts
azulene sulfonate
extract
chitosan gel
sodium azulene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211058532.1A
Other languages
Chinese (zh)
Inventor
董国勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shaanxi Dongjian Pharmaceutical Co ltd
Original Assignee
Shaanxi Dongjian Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shaanxi Dongjian Pharmaceutical Co ltd filed Critical Shaanxi Dongjian Pharmaceutical Co ltd
Priority to CN202211058532.1A priority Critical patent/CN115501328A/en
Publication of CN115501328A publication Critical patent/CN115501328A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/902—Sparganiaceae (Bur-reed family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses sodium azulene sulfonate chitosan gel and a preparation process thereof, wherein the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight: 0.2-2 parts of sodium azulene sulfonate, 0.5-2 parts of chitosan, 0.5-2 parts of collagen peptide, 0.1-0.5 part of sodium hyaluronate, 3-15 parts of plant herbal extract, 0.1-0.3 part of menthol, 0.2-1 part of carbomer, 0.5-2 parts of cellulose, 0.1-0.5 part of spice, 0.05-1 part of sterilizing preservative, 0.1-0.5 part of triethanolamine, 2-10 parts of polyalcohol humectant and 50-63 parts of purified water.

Description

Sodium azulene sulfonate chitosan gel and preparation process thereof
Technical Field
The invention relates to sodium azulene sulfonate chitosan gel, in particular to sodium azulene sulfonate chitosan gel and a preparation process thereof, belonging to the technical field of sodium azulene sulfonate chitosan gel.
Background
The sodium azulene sulfonate is an effective component of chamomile and has strong effects of diminishing inflammation, resisting bacteria and allergy and promoting mucosal metabolism; the action mechanism is as follows: inhibiting histamine release by inflammatory cells by local direct action; increase prostaglandin E2 synthesis in the mucosa, promote granulation and epithelial cell neogenesis; and can reduce the activity of pepsin.
The chitosan antibacterial hydrogel is a vaginal preparation commonly used in gynecology, has antibacterial effect, and shows characteristics similar to antibiotics because the chitosan has an inhibition effect on the growth of various bacteria. In addition, the chitosan can also promote the healing and repairing capability of tissues, and the chitosan also has the function of stopping bleeding.
In the prior art, the chitosan antibacterial hydrogel belongs to non-antibiotic medicines, can change the resistance of human skin, mucosa and vagina after long-term use, disturbs the pH value of the vagina and has a relatively warm effect; the sodium azulene sulfonate is added, the dosage of the chitosan is properly reduced, the effects of diminishing inflammation, resisting bacteria and promoting the metabolism of mucous membrane can be enhanced, and the weakly acidic environment of the vagina can be kept when the vaginal suppository is used for vagina. Therefore, the azulene sodium sulfonate chitosan gel and the preparation process thereof are urgently needed.
Disclosure of Invention
The invention aims to provide sodium azulene sulfonate chitosan gel and a preparation process thereof, and aims to solve the problems in the background art.
In order to achieve the purpose, the invention provides the following technical scheme: the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight:
Figure BDA0003825965660000011
Figure BDA0003825965660000021
as a preferred technical scheme, the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight:
Figure BDA0003825965660000022
Figure BDA0003825965660000031
as a preferred technical scheme, the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight:
Figure BDA0003825965660000032
as a preferred technical scheme of the invention, the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight:
Figure BDA0003825965660000033
Figure BDA0003825965660000041
as a preferred embodiment of the present invention, the herbal extract comprises at least 3 of aloe extract, curcuma extract, sparganium stoloniferum extract, curcuma extract, sophora flavescens extract, and myrrh extract.
As a preferable technical scheme of the invention, the sterilization preservative is at least one of quaternary ammonium salt, chlorhexidine, polyhexamethylene biguanide, methyl hydroxybenzoate, ethylparaben, propyl hydroxybenzoate, benzoic acid and lactic acid.
In a preferred embodiment of the present invention, the cellulose is one of hydroxyethyl cellulose and hydroxypropyl methyl cellulose.
In a preferred embodiment of the present invention, the polyhydric alcohol humectant is one or both of propylene glycol and glycerol.
As a preferred technical scheme, the preparation process of the sodium azulene sulfonate chitosan gel comprises the following steps:
the method comprises the following steps: 0.2-1 part of carbomer and 0.5-2 parts of cellulose are added into 20-33 parts of purified water at 45 ℃, and 0.1-0.5 part of triethanolamine is added to form a matrix;
step two: adding 0.2-2 parts of sodium azulene sulfonate, 0.5-2 parts of chitosan, 0.5-2 parts of collagen peptide and 0.1-0.5 part of sodium hyaluronate into 10-15 parts of purified water to prepare a solution a;
step three: dissolving at least 3 of Aloe extract, radix Curcumae extract, rhizoma Sparganii extract, curcumae rhizoma extract, radix Sophorae Flavescentis extract, and Myrrha extract in 10-20 parts of purified water at 80-100 deg.C to obtain solution b;
step four: 0.1 to 0.3 portion of menthol, and at least one of quaternary ammonium salt, chlorhexidine, polyhexamethylene biguanide, methyl hydroxybenzoate, ethylparaben, propyl hydroxybenzoate, benzoic acid and lactic acid as a sterilizing preservative, and adding the sterilizing preservative into 2 to 10 portions of one of polyalcohol humectant propylene glycol and glycerol to prepare solution c;
step five: adding the solutions a, b and c into the matrix, emulsifying for 15-60 min, adding perfume, and stirring.
Compared with the prior art, the invention has the beneficial effects that: the sodium azulene sulfonate chitosan gel and the preparation process thereof can be effectively used for resisting, inhibiting and killing bacteria on skin, mucosa, vagina and cervix uteri, promoting metabolism of skin mucosa and repairing skin damage and erosion by the sodium azulene sulfonate, chitosan, collagen peptide, sodium hyaluronate and plant herbal extracts.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention provides sodium azulene sulfonate chitosan gel and a preparation process thereof,
the first embodiment is as follows: the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight:
Figure BDA0003825965660000051
Figure BDA0003825965660000061
the preparation process of the sodium azulene sulfonate chitosan gel comprises the following steps:
the method comprises the following steps: 0.2 part of carbomer and 0.5 part of cellulose are added into 20 parts of purified water at the temperature of 45 ℃, and 0.1 part to 0.5 part of triethanolamine is added to form a matrix;
step two: adding 0.2 part of sodium azulene sulfonate, 0.5 part of chitosan, 0.5 part of collagen peptide and 0.1 part of sodium hyaluronate into 10 parts of purified water to prepare a solution a;
step three: dissolving at least 3 of Aloe extract, radix Curcumae extract, rhizoma Sparganii extract, curcumae rhizoma extract, radix Sophorae Flavescentis extract, and Myrrha extract in 10 parts of purified water at 80-100 deg.C to obtain solution b;
step four: 0.1 part of menthol, and at least one of a sterilizing preservative selected from quaternary ammonium salt, chlorhexidine, polyhexamethylene biguanide, methyl hydroxybenzoate, ethylparaben, propyl hydroxybenzoate, benzoic acid and lactic acid, and adding into 2 parts of one of polyalcohol moisturizers propylene glycol and glycerol to prepare a solution c;
step five: adding the solutions a, b and c into the matrix, emulsifying for 15-60 min, adding perfume, and stirring.
Example two: the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight:
Figure BDA0003825965660000062
Figure BDA0003825965660000071
the preparation process of the sodium azulene sulfonate chitosan gel comprises the following steps:
the method comprises the following steps: 0.6 part of carbomer and 1.2 parts of cellulose are added into 20-33 parts of purified water at 45 ℃, and 0.3 part of triethanolamine is added to form a matrix;
step two: 1.1 parts of sodium azulene sulfonate, 1.2 parts of chitosan, 1.2 parts of collagen peptide and 0.3 part of sodium hyaluronate, and adding the components into 10-15 parts of purified water to prepare a solution a;
step three: dissolving at least 3 of Aloe extract, radix Curcumae extract, rhizoma Sparganii extract, curcumae rhizoma extract, radix Sophorae Flavescentis extract, and Myrrha extract in 10-20 parts of purified water at 80-100 deg.C to obtain solution b;
step four: 0.2 part of menthol, and at least one of a sterilizing preservative selected from quaternary ammonium salt, chlorhexidine, polyhexamethylene biguanide, methyl hydroxybenzoate, ethylparaben, propyl hydroxybenzoate, benzoic acid and lactic acid, and adding into 6 parts of one of polyalcohol moisturizers propylene glycol and glycerol to prepare a solution c;
step five: adding the solutions a, b and c into the matrix, emulsifying for 15-60 min, adding perfume, and stirring.
Example three: the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight:
Figure BDA0003825965660000072
Figure BDA0003825965660000081
the preparation process of the sodium azulene sulfonate chitosan gel comprises the following steps:
the method comprises the following steps: adding 1 part of carbomer and 2 parts of cellulose into 33 parts of purified water at the temperature of 45 ℃, and adding 0.5 part of triethanolamine to form a matrix;
step two: adding 2 parts of sodium azulene sulfonate, 2 parts of chitosan, 2 parts of collagen peptide and 0.5 part of sodium hyaluronate into 15 parts of purified water to prepare a solution a;
step three: dissolving at least 3 of Aloe extract, radix Curcumae extract, rhizoma Sparganii extract, curcumae rhizoma extract, radix Sophorae Flavescentis extract, and Myrrha extract in 10-20 parts of purified water at 80-100 deg.C to obtain solution b;
step four: 0.3 part of menthol, and at least one of a sterilizing preservative selected from quaternary ammonium salt, chlorhexidine, polyhexamethylene biguanide, methyl hydroxybenzoate, ethylparaben, propyl hydroxybenzoate, benzoic acid and lactic acid, and adding into 10 parts of one of polyalcohol moisturizers propylene glycol and glycerol to prepare a solution c;
step five: adding the solutions a, b and c into the matrix, emulsifying for 15-60 min, adding perfume, and stirring.
Wherein the herbal extract comprises at least 3 of Aloe extract, radix Curcumae extract, rhizoma Sparganii extract, curcumae rhizoma extract, radix Sophorae Flavescentis extract, and Myrrha extract.
Further, the bactericidal preservative is at least one of quaternary ammonium salt, chlorhexidine, polyhexamethylene biguanide, methylparaben, ethylparaben, propylparaben, benzoic acid and lactic acid.
Further, the cellulose is one of hydroxyethyl cellulose and hydroxypropyl methyl cellulose.
Wherein the polyalcohol humectant is one or two of propylene glycol and glycerol.
Example four: the sodium azulene sulfonate chitosan gel sterilization test steps are as follows:
(1) Equipment
1. Test strains: escherichia coli (8099), candida albicans (ATCC 10231) for 5 generations, staphylococcus aureus (ATCC 6538) for 5 generations, and Escherichia coli (8099) for 5 generations.
2. 3% bovine serum albumin, tryptone physiological saline solution, standard hard water: the common nutrient agar culture medium is provided by Beijing road bridge technology, inc.
3. 0.03mol/L Phosphate Buffer Solution (PBS).
4. Neutralizing agent: 2.0% Tween-80 +1.0% lecithin +0.5% sodium thiosulfate in PBS.
5. A sterile scale suction pipe, a sterile plate, a sterile test tube, a constant temperature incubator and the like.
(2) Sample (I)
1. Sample preparation: sodium azulene sulfonate chitosan gel.
2. Sample treatment: according to GB15979-2002 hygienic Standard for Disposable sanitary articles, 5mL of sample solution is directly tested.
(3) Method of producing a composite material
1. According to the technical Specification for Disinfection (Ministry of health 2002.11) and GB 15979-2002.
2. The neutralizer identification test adopts a suspension method identification test and a staphylococcus aureus (ATCC 6538) neutralizer selection test, the sample concentration is stock solution, and the action time is 20min. Candida albicans (ATCC 10231) neutralizer selection test, wherein the sample concentration is stock solution, and the action time is 20min. The test temperature was 20 seconds 1 ℃.
3. The sterilization test is a suspension test. The test temperature was 20 ℃ and 1 ℃ and the test was repeated three times.
(4) Results
1. Staphylococcus aureus neutralizer identification test
1.1 the first group was aseptically grown and the second group was aseptically grown for each trial. The second group has more growth bacteria than the first group, but less growth bacteria than the first group, and error rates of the third group 3, 4, and 5 are 6.14%, 2.67%, and 8.00%, respectively
The serial numbers and representations of the groups in the table are the same as those in the Disinfection Specification (Ministry of health 2002.11).
1.2 neutralizer identity test results are shown in Table 1.
TABLE 1 Staphylococcus aureus neutralizer identification test results
Figure BDA0003825965660000101
2. Candida albicans neutralizer identification test
2.1 the first group was aseptically grown and the second group was aseptically grown for each trial. The number of growing bacteria in the second group was greater than that in the first group, but less than that in the 3 rd, 4 th and 5 th groups, and the error rates among the three groups 3, 4 and 5 were 5.13%, 1.73% and 4.50%, respectively. The numbers and representations of the groups in the table are the same as those in the Disinfection Specification (section for health 2002.11).
2.2 neutralizer identity test results are shown in Table 2.
TABLE 2 Candida albicans neutralization agent identification test results
Figure BDA0003825965660000111
3. Bactericidal effect on test bacteria
The raw liquid of the sodium azulene sulfonate chitosan gel acts for 20min, and the average sterilization rate of the raw liquid to escherichia coli (8099) and staphylococcus aureus (ATCC 6538) can reach more than 90 percent: the average sterilization rate of the candida albicans (ATCC 10231) can reach more than 90 percent. The experiment was repeated three times. The results are shown in tables 3, 4 and 5.
TABLE 3 Sterilization effect of sodium azulene sulfonate chitosan gel stock solution on Escherichia coli
Figure BDA0003825965660000112
Note: average viable count of positive control group was 2.66x10 4 fu/mL(2.4x10 4 cfu/mL～2.7x10 4 cfu/mL)
Sterile growth of negative control group
TABLE 4 Bactericidal Effect of sodium azulene sulfonate chitosan gel stock solution on Staphylococcus aureus
Figure BDA0003825965660000121
Note: average viable count of positive control group is 2.58x10 4 cfu/mL(25x10 4 cfu/mL～2.8x10 4 cfu/mL)
Negative control group sterile growth
TABLE 5 Sterilization Effect of sodium azulene sulfonate Chitosan gel stock solution on Candida albicans
Figure BDA0003825965660000122
Note: average viable count of positive control group was 2.88x10 4 cfu/mL(2.6x10 4 cfu/mL～2.9x10 4 cfu/mL)
Negative control group sterile growth
4. Conclusion
1. The neutralizing agent identification experiment shows that the PBS solution of the neutralizing agent 2.0% of Tween-80 +1.0% of lecithin +0.5% of sodium thiosulfate can completely neutralize the detected sample 'azulene sodium sulfonate chitosan gel'. The neutralizing agent and the neutralized product have no influence on test bacteria such as Escherichia coli (8099), staphylococcus aureus (ATCC 6538), candida albicans (ATCC 10231) and culture medium.
2. Under the condition that the test temperature is 20 ℃ and 1 ℃, the raw liquid of the sample 'azulene sodium sulfonate chitosan gel' is acted for 20min, the average sterilization rate on escherichia coli (8099) and staphylococcus aureus (ATCC 6538) can reach more than 90%, and the average sterilization rate on candida albicans (ATCC 10231) can reach more than 90%.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims (9)

1. The sodium azulene sulfonate chitosan gel and the preparation process thereof are characterized in that the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight:
Figure FDA0003825965650000011
2. the sodium azulene sulfonate chitosan gel and the preparation process thereof according to claim 1, which is characterized in that: the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight:
Figure FDA0003825965650000012
Figure FDA0003825965650000021
3. the sodium azulene sulfonate chitosan gel and the preparation process thereof according to claim 1, characterized in that: the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight:
Figure FDA0003825965650000022
4. the sodium azulene sulfonate chitosan gel and the preparation process thereof according to claim 1, which is characterized in that: the sodium azulene sulfonate chitosan gel is prepared from the following raw materials in parts by weight:
Figure FDA0003825965650000023
Figure FDA0003825965650000031
5. the sodium azulene sulfonate chitosan gel and the preparation process thereof according to claim 1, characterized in that: the herbal extract comprises at least 3 of Aloe extract, radix Curcumae extract, rhizoma Sparganii extract, curcumae rhizoma extract, radix Sophorae Flavescentis extract, and Myrrha extract.
6. The sodium azulene sulfonate chitosan gel and the preparation process thereof according to claim 1, characterized in that: the antiseptic is at least one of quaternary ammonium salt, chlorhexidine, polyhexamethylene biguanide, methyl hydroxybenzoate, ethylparaben, propyl hydroxybenzoate, benzoic acid, and lactic acid.
7. The sodium azulene sulfonate chitosan gel and the preparation process thereof according to claim 1, characterized in that: the cellulose is one of hydroxyethyl cellulose and hydroxypropyl methyl cellulose.
8. The sodium azulene sulfonate chitosan gel and the preparation process thereof according to claim 1, which is characterized in that: the polyalcohol humectant is one or 2 of propylene glycol and glycerol.
9. The sodium azulene sulfonate chitosan gel and the preparation process thereof according to claim 1, characterized in that: the preparation process of the sodium azulene sulfonate chitosan gel comprises the following steps:
the method comprises the following steps: 0.2-1 part of carbomer and 0.5-2 parts of cellulose are added into 20-33 parts of purified water at 45 ℃, and 0.1-0.5 part of triethanolamine is added to form a matrix;
step two: adding 0.2-2 parts of sodium azulene sulfonate, 0.5-2 parts of chitosan, 0.5-2 parts of collagen peptide and 0.1-0.5 part of sodium hyaluronate into 10-15 parts of purified water to prepare a solution a;
step three: dissolving at least 3 of Aloe extract, radix Curcumae extract, rhizoma Sparganii extract, curcumae rhizoma extract, radix Sophorae Flavescentis extract, and Myrrha extract in 10-20 parts of purified water at 80-100 deg.C to obtain solution b;
step four: 0.1-0.3 part of menthol, and at least one of quaternary ammonium salt, chlorhexidine, polyhexamethylene biguanide, methyl hydroxybenzoate, ethylparaben, propyl hydroxybenzoate, benzoic acid and lactic acid as a sterilizing preservative, and adding into 2-10 parts of one of polyalcohol humectant propylene glycol and glycerol to prepare solution c;
step five: adding the solutions a, b and c into the matrix, emulsifying for 15-60 min, adding the perfume, and stirring.
CN202211058532.1A 2022-08-30 2022-08-30 Sodium azulene sulfonate chitosan gel and preparation process thereof Pending CN115501328A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211058532.1A CN115501328A (en) 2022-08-30 2022-08-30 Sodium azulene sulfonate chitosan gel and preparation process thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211058532.1A CN115501328A (en) 2022-08-30 2022-08-30 Sodium azulene sulfonate chitosan gel and preparation process thereof

Publications (1)

Publication Number Publication Date
CN115501328A true CN115501328A (en) 2022-12-23

Family

ID=84502261

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211058532.1A Pending CN115501328A (en) 2022-08-30 2022-08-30 Sodium azulene sulfonate chitosan gel and preparation process thereof

Country Status (1)

Country Link
CN (1) CN115501328A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116850245A (en) * 2023-08-22 2023-10-10 陕西东健药业有限公司 Deuterium-depleted water traditional Chinese medicine combined eye care solution and preparation method thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116850245A (en) * 2023-08-22 2023-10-10 陕西东健药业有限公司 Deuterium-depleted water traditional Chinese medicine combined eye care solution and preparation method thereof

Similar Documents

Publication Publication Date Title
CN111202822A (en) Gynecological external antibacterial spray and preparation method thereof
CN103182070B (en) External composition, and preparation and application thereof
CN108158995A (en) A kind of gynaecology's anti-bacteria foaming agent containing chitosan and preparation method thereof
CN104043098A (en) Antimicrobial peptide freeze-dried preparation for treating colpitis and preparation method thereof
CN115501328A (en) Sodium azulene sulfonate chitosan gel and preparation process thereof
CN111449973A (en) Foaming agent for restoring microecological balance of female vagina and preparation method thereof
CN105169456B (en) A kind of medical bio hemorrhoid hydrogel functional dressing and preparation method thereof
CN103191408B (en) Medicine composition and gel for treating colpitis and applications thereof
CN109010124B (en) Marine refined gynecological antibacterial gel and preparation method thereof
CN110917120A (en) Sticky antibacterial repairing material and preparation method and application thereof
CN108186738B (en) Gynecological gel containing periplaneta americana extract and preparation method thereof
EP1128809B1 (en) Aqueous ophthalmic formulations comprising chitosan
CN102240260B (en) Medicament for treating colpoxerosis and preparation method thereof
CN111803624A (en) Skin antibacterial gel preparation containing transfer factor and preparation method thereof
CN113456735B (en) Inactivated probiotic herbal gel and preparation method and application thereof
CN111096934B (en) Gel for inhibiting acne
CN114652748A (en) Preparation method and application of medical gynecological lotion containing stem cell bacteriostatic factors
EP3400950A1 (en) Bladder instillation composition containing chondoitin sulfate (20 mg/ml), hyaluronic acid (16 mg/ml) and phosphate buffer (ph 6,1 to 7,9) with an improved storage stability for the treatment of cystitis
CN100388949C (en) Lysostaphin freeze dried powder used for preventing and treating cattle edometritis
CN103191163B (en) Skin wound repairing pharmaceutical composition
CN113230205B (en) Gynecological gel preparation and preparation method and application thereof
CN111773259B (en) Plant liquid medicine gel preparation for repairing vaginal mucosa injury and preparation method thereof
DE202017103288U1 (en) Composition for the treatment of inflammatory diseases of the genitourinary tract in the form of a high-dose combination of active ingredients
CN107596075A (en) A kind of drug regimen composition formula for treating cervicitis and purposes
CN110665002B (en) Antibody preparation for preventing and treating bovine viral diarrhea and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination